Duclos P
Division de l'immunisation des enfants, Laboratoire de lutte contre la maladie, Ottawa, Ontario, Canada.
Sante. 1994 May-Jun;4(3):215-20.
Although modern vaccines are usually well tolerated and efficacious, no vaccine is totally safe nor totally efficacious and adverse events have been reported following the use of each of them. International collaboration in the use, testing, and surveillance of vaccines would help limit these problems. National immunization programs must rely on comprehensive and timely surveillance and have the capability to react quickly to minimise negative outcomes. In each individual case, it may be difficult to demonstrate or rule out a relationship between a vaccine and an adverse event because there is usually no clear marker of etiology. Postmarketing surveillance of vaccines could be defined as the coordinated, structured, systematic, ongoing collection of data on the impact of licensed vaccines and their subsequent epidemiologic analysis and dissemination to manufacturers, regulators, health care providers, and the public. Managers of immunization programs have the responsibility for determining the risks associated with each vaccine, for constantly weighing the risks and benefits of vaccine use, and for minimizing the risks. Postmarketing surveillance of illness following administration of immunizing agents permits: 1) identification of illness or other side effects caused by immunizing agents; 2) estimation of the incidence of serious side effects of immunization; 3) monitoring for unusually high rates of adverse events (including lot-by-lot surveillance); 4) raising of health care providers' awareness to the risks and/or safety measures in administering vaccines; 5) identification of issues that require epidemiological research; and 6) identification of problems that require immediate epidemiological investigation.(ABSTRACT TRUNCATED AT 250 WORDS)
尽管现代疫苗通常耐受性良好且有效,但没有一种疫苗是完全安全或完全有效的,使用每种疫苗后都有不良事件的报告。在疫苗的使用、测试和监测方面开展国际合作将有助于限制这些问题。国家免疫规划必须依靠全面和及时的监测,并具备迅速做出反应以尽量减少负面结果的能力。在每个具体案例中,可能很难证明或排除疫苗与不良事件之间的关系,因为通常没有明确的病因标志物。疫苗上市后监测可定义为对已获许可疫苗的影响进行协调、有组织、系统、持续的数据收集,以及随后进行的流行病学分析,并向制造商、监管机构、医疗服务提供者和公众传播。免疫规划管理人员有责任确定每种疫苗相关的风险,不断权衡疫苗使用的风险和益处,并将风险降至最低。对免疫制剂接种后疾病的上市后监测可实现以下目标:1)识别免疫制剂引起的疾病或其他副作用;2)估计免疫严重副作用的发生率;3)监测异常高的不良事件发生率(包括逐批监测);4)提高医疗服务提供者对接种疫苗风险和/或安全措施的认识;5)识别需要进行流行病学研究的问题;6)识别需要立即进行流行病学调查的问题。(摘要截选至250词)